Bladder Cancer
- Other Urinary, Urinary BladderA Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint InhibitorPrincipal Investigator: Michael Hurwitz
- Urinary BladderA Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial CarcinomaPrincipal Investigator: Joseph Kim
- Other UrinaryA Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial CarcinomaPrincipal Investigator: Daniel P. Petrylak
- Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)Principal Investigator: Joseph Kim
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim